Advice
Recommended for restricted use within NHS Scotland
REASONS FOR ADVICE
Moxifloxacin (Avelox), a new fluoroquinolone antibiotic, should be reserved as a second line treatment for community acquired pneumonia in accordance with British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) guidance.
Download detailed advice22KB (PDF)
Medicine details
- Medicine name:
- Moxifloxacin (Avelox®)
- SMC ID:
- 69/03
- Indication:
- Community acquired pneumonia
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 October 2003